Seeking Alpha
24 Oct 2026, 04:37 UTC · 1h ago
Impact · against what's priced in
Novartis is discussing trial results for remibrutinib in Relapsing Multiple Sclerosis, providing positive pipeline visibility for its neuroscience unit. As this is a technical update on a development-stage asset, the immediate impact is marginally positive but limited.
No priced-in read yet
Which stocks this story touches
More positive than 62% of ticker scores this week
The company is discussing trial results for Remibrutinib in Relapsing Multiple Sclerosis, which is generally a positive development for its pipeline.
Continue reading
5 related stories
The discussion of REMODEL trial results for remibrutinib suggests positive progress in the company's Multiple Sclerosis pipeline.
Read from the article alone
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
8h ago
—
NVS hasn't traded since this ran. Last close $151.12 (Oct 23); the reaction starts at the next open.
NVS chart →
